DFIB Cardiac Science (MM)

$925,000 Payment to Cardiac Science Settles Dispute IRVINE, Calif., Aug. 9 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. (NASDAQ:DFIB), a leading manufacturer of life-saving automatic public-access defibrillators (AEDs), announced today that it has settled its patent infringement lawsuit it had brought against privately-held Defibtech, L.L.C. in the United States District Court for the District of Minnesota in April, 2003. As a condition of settlement, Cardiac Science will receive a cash payment in the amount of $925,000. Cardiac Science's allegations of infringement by Defibtech of United States Patent No.'s 5,579,919, 5,700,281 and 6,038,473 and all of Defibtech's assorted counterclaims have been fully resolved. Other terms and conditions of the settlement remain confidential. Cardiac Science's Chairman and CEO Raymond W. Cohen said, "This settlement further demonstrates the strength of our patent portfolio and serves as yet another example where Cardiac Science has prevailed when our intellectual property assets were threatened by a competitor. We will continue to be vigilant in the marketplace in defending our inventions. And as our track record demonstrates, when necessary, we will not shy away from seeking remedy in court in order to dissuade our competitors, irrespective of their size or standing in the marketplace, from inappropriately employing our patented AED features and technology. To that end, we fully intend to continue to aggressively pursue the outstanding patent litigation suit which we brought against Philips in early 2003 until it is resolved to our satisfaction and we receive sufficient recompense." About Cardiac Science Cardiac Science develops, manufactures and markets a complete line of Powerheart(R) brand, automatic public access defibrillators (AEDs), and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The company has over 70 issued U.S. patents relating to its external defibrillation products and technology. For more information on Cardiac Science please visit http://www.cardiacscience.com/ or call (949) 797-3800. This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time the company, or its representatives, have made or may make forward-looking statements orally or in writing. The words "estimate," "potential," "intended," "expect," "anticipate," "believe," and similar expressions or words are intended to identify forward looking statements. Such forward-looking statements include, but are not limited to the strength of Cardiac Science's patents and its ability to receive recompense based on its allegations of patient infringement against Philips Medical. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company's Form 10-K for the year ending December 31, 2004, subsequent quarterly filings, and other documents filed by the Company with the Securities and Exchange Commission. Contact: Matt Clawson (Investors), or Kenneth Olson Len Hall (Media) Chief Technology Officer Allen & Caron Inc Cardiac Science, Inc. (949) 474-4300 (949) 797 3800 DATASOURCE: Cardiac Science, Inc. CONTACT: Investors, Matt Clawson, , or Media, Len Hall, , both of Allen & Caron Inc, +1-949-474-4300, for Cardiac Science Inc.; or Kenneth Olson, Chief Technology Officer, Cardiac Science, Inc., +1-949-797-3800, Web site: http://www.cardiacscience.com/

Copyright